Encore medical divests non-core US consumer line to Biomedical:
This article was originally published in Clinica
Executive Summary
Encore Medical is to sell its Slendertone US consumer business for approximately $6.8m in cash to Bio-Medical Research, the Irish company that developed, manufactures, distributes and owns all intellectual property rights to the Slendertone product line. The transaction, expected to close by the end of June, encompasses the Slendertone inventory and all of Encore's US distribution rights to the products. Proceeds from the sale will be invested into the Austin, Texas company's core surgical implant and orthopaedic rehabilitation businesses. Encore had acquired the US Slendertone unit as part of its acquisition of the electrotherapy company Compex Technologies, which was completed in February 2006 (see Clinica No 1196, p 14).
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.